Request Appointment
353 East 68th StreetNew York, NY 10065
Overview of Dr. Rosenberg
Dr. Jonathan Rosenberg is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Harvard Medical School and has been in practice 20 years. Dr. Rosenberg accepts several types of health insurance, listed below. He is one of 502 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2000 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
Harvard Medical SchoolClass of 1997
Certifications & Licensure
CT State Medical License 2023 - 2026
NY State Medical License 1998 - 2026
PA State Medical License 2022 - 2026
NJ State Medical License 2019 - 2025
NC State Medical License 2020 - 2022
MA State Medical License 2008 - 2013
CA State Medical License 2000 - 2009
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Enno Ercklentz Endowed Chair Memorial Sloan Kettering Cancer Center
Publications & Presentations
PubMed
- Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer.Michal Sternschuss, Jonathan E Rosenberg
Future Oncology. 2025-03-25 - Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma.Kwanghee Kim, Syed M Alam, Fengshen Kuo, Ziyu Chen, Wesley Yip
European Urology. 2025-03-01 - 17 citationsAdjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.Andrea B Apolo, Karla V Ballman, Guru Sonpavde, Stephanie Berg, William Y Kim
The New England Journal of Medicine. 2025-01-02
Journal Articles
- Enfortumab Vedotin in Previously Treated Advanced Urothelial CarcinomaJonathan E Rosenberg, Daniel P Petrylak, The New England Journal of Medicine
Lectures
- CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with m...2019 ASCO Annual Meeting - 6/1/2019
- EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who pre...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- ASCO 2018: Dr. Jonathan E. Rosenberg on Updated in Genitourinary OncologyJune 2018
- ASCO 2018: Dr. Jonathan E. Rosenberg on Updated in Genitourinary OncologyJune 2018
Press Mentions
More Progress for Bladder-Sparing Strategies in Muscle-Invasive CancerFebruary 19th, 2025- Response Duration After Stopping Enfortumab Vedotin in Bladder CancerNovember 15th, 2024
- Promising OS at 5 Years with Chemo-Free Combo in Urothelial CancerNovember 8th, 2024
- Join now to see all
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPOGreat West PPO
Harvard Pilgrim HMO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
UniCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
